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The effects ofbeta-human chorionic gonadotrophin on the in vitro growth of
bladder cancer cell lines
DJ Gillott, RK Iles and T Chard
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Summary The effects of human chorionic gonadotrophin (hCG) and its subunits on in vitro bladder cancer
cell growth have been assessed using the a tetrazolium salt reduction assay (MTT). Intact hCG, a-hCG and f,-
core hCG all had no effect on cell growth, while fl-hCG increased MTT reduction in all four bladder cancer
lines tested. The magnitude of ,B-hCG stimulation was maximal in the T24 line, which does not itself produce
P-hCG and appeared to be correspondingly lower in ,B-hCG-secreting lines. The addition of antibodies to f,-
hCG inhibited MTT reduction among high secretors but failed to inhibit MTT reduction in non-fl-hCG
producers. These results are consistent with the poor prognosis associated with ,B-hCG expression by bladder
tumours in vivo and suggest an autocrine/paracrine stimulation of tumour growth by endogenously produced f,-
hCG.
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Human chorionic gonadotrophin (hCG) is a member of the
family of glycoprotein hormones, including follicle-stimula-
tion hormone (FSH), luteinising hormone (LH) and thyroid-
stimulating hormone (TSH), all of which are heterodimeric
and share a common a-subunit. Each hormone has a unique
P-subunit, although the f-chain of hCG exhibits 81%
homology with that of LH and may have arisen from the
LH gene following duplication and readthrough in the 3'
direction (Fiddes and Talmadge, 1984). In primates and
equids, CG originates from the conceptus and rescues the
corpus luteum by binding to an LH receptor (Yoshimi et al.,
1969; Braunstein et al., 1976; Bolton et al., 1980). The lone f-
subunit cannot bind to the LH receptor, the intact
heterodimer being required for both binding and activation
(Pierce and Parsons, 1981).
The ectopic production of fl-hCG by a proportion of
bladder cancers has been reported by several authors
(Rodenburg et al., 1985; Dexeus et al., 1986, Iles et al.,
1987) and cannot be accounted for simply by gene
duplication or rearrangement. Consequently, it is likely that
the control mechanisms governing fl-hCG expression are
abnormal in secreting tumours (Iles et al., 1988). As a clinical
marker fl-hCG may have some value for monitoring in
therapy (Marcillac et al., 1993); high levels have been
associated with both radio-resistance and metastases
(Martin et al., 1989), but current opinion holds that the
secretion is an epiphenomenon of little clinical significance
(Jacobsen et al., 1990; Smith et al., 1994). However, a recent
study carried out in this unit showed that 50% of T2/T3
patients had elevated urinary fl-hCG (>3.74 IU mmol-'
creatinine), and 90% of these went on to develop metastases,
while only 3% of the non-expressing group developed
metastatic disease. In addition, survival curves for these
patients, when divided into P-hCG expressors and non-
expressors, show approximately 10% and 60% survival
respectively at 17 months, suggesting a valuable prognostic
function (Iles et al., 1996).
We have also shown that primary cultures of normal
urothelium can secrete fl-hCG (Iles et al., 1990). The
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production of fl-hCG by normal urothelium, together with
a complete absence of intact hCG, suggests the possibility of
a hitherto unknown biological role for this molecule. We
have investigated this idea further by examining the effects of
fl-hCG on the growth of various bladder cancer cell lines in
vitro.
Materials and methods
Cell lines
The f-human chorionic gonadotrophin-secreting bladder
cancer cell lines RTI12, SCaBER and 5637 (Iles et al.,
1987) were obtained from the American Type Culture
Collection (Rockville, MD, USA). The non-secreting bladder
cancer line T24 (Bubenik et al., 1973) was obtained from Dr
J Masters of the Institute of Urology, London, UK.
Hormones and antibodies
Intact hCG along with free a- and fl-subunits were derived
from NIH preparation CR123 obtained from Dr Diana
Blithe (Endocrine Branch, The National Institute of Child
Health and Human Development, NIH, Bethesda, MD,
USA). Drs RE Canfield and S Birken ofColumbia University
have purified all the CR series of hCG reference standards,
i.e. intact hCG and free cx- and fl-subunits, for the NIH and
the WHO (Birken et al., 1990). These have been distributed
worldwide and have been used as the First International
Reference Preparation of hCG and free subunits for
immunoassay and the Third International standard for
intact hCG bioassay. Here we used the preparation labelled
123 of the CR series, which was first released in 1977. The
purity of these preparations is well recognised. However,
several degradation products of hCG metabolism have
recently been recognised, the ultimate step being the
formation of urinary f-core. Intermediate steps include the
nicking of the f-subunit at residues 45-50. The extent of
such nicking varies with each preparation and CR123 has
been estimated to contain 10-16% nicked fl-chains (Birken
et al., 1991). The in-house preparation of highly purified fi-
core used in these experiments has been previously described
by Lee et al. (1991).
Sheep antisera 750 and 752 were prepared in-house,
following immunisation with free fl-hCG isolated from
pregnancy urine. These antisera were found to react with
only the free f-subunit of hCG but not intact hCG, LH,fi-hCG growth factor actiit
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FSH, TSH or the free a-subunit and the hCG urinary
metabolite f-core. (Iles et al. unpublished data). These
polyclonal sheep antisera are now commercially available
from Polyclonal Antibodies, Llyndysal Dyfed, Wales, UK). A
control antisera of normal (non-immune) sheep sera was
obtained from Polyclonal Antibodies.
MTT assay
The 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bro-
mide (MTT) assay (Mosman, 1983) was used to estimate cell
number following exposure to intact hCG, free a- and f-
subunits, urinary metabolite fl-core and to anti-,B-hCG
antisera.
Microtitre plates (Coming 96-flat-bottomed wells) were
seeded with 200 pl of 0.1 x 106 ml-' cell suspension (20 000
cells per well) in RPMI + 10% fetal calf serum (FCS) for 24
h before the replacement of media by fresh culture media
containing test materials (0-500 ng ml-' ligands or 1:1000
dilution of antisera). Plates were then incubated for a further
36 h, followed by 1 h incubation in fresh medium, then
addition of 20 ul millipore filtered MTT (5 mg ml-' in PBS).
After 4 h incubation all fluid was removed and 100 pl of
acidified isopropanol (containing 0.04 M HCI) was added to
each well and maintained at room temperature for 15 min to
allow formazan crystals to dissolve. Absorbance measure-
ments were carried out at 570 nm against a 630 nm blank; at
least three replicates of each treatment were included. Results
were expressed as optical density as a per cent of untreated
controls.
Results
Stimulation by hCG andfragments
Intact hCG, a-hCG and fl-core had no effect on the growth
of any of the cell lines, while 25 ng ml-' ,B-hCG produced a
152% increase in MTT reduction by T24 cells; (Figure 1,
Table I). 5637, SCaBER and RT112 were stimulated to a
lesser extent increasing MTT reduction by 132, 112 and
116% of controls respectively (Figure 2, Table II).
Effect ofanti-#-subunit antisera
Concurrent addition of specific antisera with the fl-hCG-
containing media eliminated the stimulatory effect of the fi-
hCG on the responding cell lines. This was best illustrated
when antisera was concurrently added to escalating doses (0-
50 ng ml-') of free fl-hCG in cultures of the T24 cell line
(which does not secrete its own fl-hCG). The dose-response
curve to the P-hCG was obliterated with co-addition of the
anti-f-subunit antisera and MTT reduction matched that of
controls (Figure 3). This was not seen when non-immune
control sheep serum (NSS) was used (data not shown).
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Table I Dose-effect of hCG and subunits on T24 cell growth as
measured by MTT reduction relative to untreated controls
Intact hCG cx-hCG fl-hCG #-core
Ligand (per cent (per cent (per cent (per cent
(ng ml-1) ofcontrol) of control) ofcontrol) ofcontrol)
0 100.0±4.2 100.0+ 10.0 100.0± 14.1 100.0+ 7.3
1.57 90.9 ±5.2 108.1 +4.2 118.0+4.5 95.9+ 5.2
3.13 87.8±2.9 112.9±8.5 123.2+3.1 94.2±6.9
6.25 86.5+ 3.7 105.4+5.7 130.4+9.7 98.9+ 3.2
12.50 84.4+4.1 102.6+6.3 139.5 ±7.5 91.2+ 8.7
25.00 90.4+ 17.5 104.2+ 7.7 154.0 ± 10.2 99.7+ 9.9
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Figure 2 A comparison of the dose-dependent growth response
of four epithelial bladder cancer cell lines (T24, SCaBER, RT112
and 5637) to fl-hCG.
Table H Dose-effect of f,-hCG on cell growth of ,B-hCG-
expressing (SCaBER, RTI12 and 5637) and non-expressing (T24)
cell lines as measured by MTT reduction relative to untreated
controls
T24 5637 SCaBER RT112
fl-hCG (per cent (per cent (per cent (per cent
(ng ml-') of control) ofcontrol) ofcontrol) ofcontrol)
0 100.0+14.1 100.0+7.3 100.0+15.4 100.0+5.7
1.57 118.0+4.5 102.8+6.8 98.6+2.7 93.7+4.7
3.13 123.2+3.1 106.7+9.2 102.4+4.6 94.7+5.9
6.25 130.4+9.7 107.6+6.5 99.0+2.6 99.2+9.0
12.50 139.5+ 7.5 116.2+9.4 101.7+4.8 100.8 ±7.3
25.00 154.0+10.2 132.0+7.0 111.8+7.7 115.5+ 16.6
Antisera to free f-subunit at a 1:1000 dilution added to
cell lines SCaBER and 5637 (lines that synthesised and
secreted their own fl-hCG) lowered MTT reduction to 60%
and 70% of control levels respectively. However, the control
1 E
c 1 0
oco1
.- I 0- 0
C 44
O)
L
0-.-- -0
0 4L -0 1
.2
0
iCG
0 5 10 15 20 25 30
Ligand (ng mF1)
Figure 1 Dose-dependent effects of hCG, free a- and fl-subunits
and metabolite fl-core on the growth of the T24 cell line as
measured by tetrazolium salt reduction expressed as a percentage
of untreated control values.
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Figure 3 Abolition of the dose-dependent fl-hCG growth
stimulation of T24 cells by the co-addition of anti-fl-hCG
antibodies to the cultures.fl-hCG growth factor actvtx
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NSS at the same dilution did not alter MTT reduction
relative to controls. Furthermore, the T24 cell line (which
does not secrete f-hCG) was unaffected by the addition of
the fl-subunit antisera (Figure 4).
Discussion
The observation that 70% of established bladder cancer cell
lines and normal urothelial cells established as finite lifespan
cultures secrete variable quantities of,-hCG prompted our
investigation into a putative biological activity of free fl-hCG
(Iles, 1991). The MTT assay clearly demonstrates an increase
in cell numbers following fl-hCG treatment but no such effect
with intact hCG or oc-hCG (Figure 1). It is interesting to note
that f-core had no effect either. This metabolite, which has a
shortened carboxy terminus, fewer carbohydrate residues and
several nicks in the amino acid chain (Birken et al., 1988) is
found excreted in the urine. The absence ofan effect with this
molecule provides further evidence for the specificity of the
growth effect observed with the free fl-subunit.
The effect of exogenous f-hCG on responding cell lines
was inhibited in a dose-dependent manner by antisera to fi-
hCG (Figure 3). This suggests a highly specific type of
interaction, possibly mediated by a receptor, as normal sheep
serum produced no diminution of growth response in any of
the lines. The growth response was highest in the T24 cell
line, which does not itself secrete fl-hCG, while higher
secretors exhibited less growth stimulation. This implies that
fl-hCG producers may be self-stimulating populations in vitro
(or indeed, in vivo), high level producers being incapable of
further stimulation by exogenous fl-hCG. Alternatively, there
might be more than one subpopulation of urothelial cells,
with secretors and responders in varying proportions that
determine overall production or response rates. The recently
elucidated three-dimensional structure of f-hCG (Lapthorn et
al., 1994) includes at its centre a distinctive arrangement of
protein chain folds that is stabilised by six disulphide bonds
and known as the cysteine knot motif. This motif is found in
at least three growth factors: nerve cell growth factor (NGF),
transforming growth factor (TGF-fl2) and platelet-derived
growth factor (PDGF-BB). These molecules are able to bind
to their receptors as homodimers, a possibility that could
exist with fl-hCG and should be investigated further.
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Figure 4 The effect of 1:1000 dilution anti-fl-hCG antibodies in
media on cell growth, as measured by tetrazolium salt reduction,
for fl-hCG secreting cell lines 5637 and SCaBER and non-
expressing cell line T24 compared with untreated controls and
cells exposed to normal (non-immune) sheep sera (NSS) at 1:1000
dilution. O, Control; f3, NSS(1:1000); M, anti-free ,B-hCG.
When no exogenous /3-hCG was added, antisera against /3-
hCG considerably inhibited growth in the high-producing
lines such as SCaBER, with little or no growth inhibition
perceived in the non-secreting T24 line (Figure 4). This
provides further evidence for the validity and specificity of
the observed effects of the subunit itself and constitutes
important new evidence for an autocrine/paracrine effect of
f-hCG in urothelial cell carcinomas, while suggesting a
possible mechanism for some of the poor prognostic
associations with fl-hCG that have been reported.
In conclusion, fl-hCG (but not intact hCG, oa-hCG or 1l-
core) is able to specifically increase cell growth in bladder
epithelial bladder cancer lines, this effect is mediated by a
specific interaction that is obliterated by anti-f,-hCG serum.
These findings could be explained if it is postulated that the
free f-subunit acts as a growth factor.
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